Evaluation of Erythroid Disturbance and Thiol-Disulphide Homeostasis in Patients with Psoriasis
Table 3
Hematologic, inflammatory, and disulphide-homeostasis studies of the groups.
Healthy controls ()
Patients with PASI ≤ 10 ()
Patients with PASI > 10 ()
-value
Hemoglobin (g/dL)
Median; IQR
13.5; 1.1
13.10; 0.9
13.50; 2.3
0.133
(min, max)
(12.1, 15.6)
(12.1, 15.8)
(12.0, 15.9)
Mean corpuscular volume (fL)
Mean ± SD
84.76 ± 3.87
89.0 ± 4.3
89.0 ± 5.0
0.001
(min, max)
(79, 93)
(80, 95)
(83, 95)
Red cell distribution width (%)
Median; IQR
12.8; 0.8
13.0; 0.7
14.5; 1.2
0.001
(min, max)
(11.8, 14.6)
(12.0, 14.2)
(13.4, 16.1)
Leukocyte count (×109/L)
Mean ± SD
7.4 ± 1.3
7.4 ± 2.2
7.0 ± 1.8
0.495
(min, max)
(3.9, 9.8)
(1.4, 12.0)
(1.2, 11.3)
C-reactive protein (mg/dl)
Median; IQR
3.5; 1.7
8.9; 4.4
12.6; 6.35
0.001
(min, max)
(2.2, 18.9)
(2.5, 21.0)
(3.1, 22.0)
Native thiol (µmol/L)
Median; IQR
423.05; 89.5
385.83; 121.72
379.40; 94.05
0.056
(min, max)
(129.7, 491.9)
(174.7, 550.9)
(216.7, 538.8)
Total thiol (µmol/L)
Median; IQR
456.05; 84.2
423.60; 119.36
433.00; 94.30
0.199
(min, max)
(139.8, 533.2)
(228.1, 610.5)
(249.6, 569.2)
Disulphide (µmol/L)
Median; IQR
15.03; 8.80
19.77; 5.79
19.95; 5.33
0.001
(min, max)
(1.9, 36.0)
(6.5, 36.0)
(11.1, 30.1)
Disulphide/native thiol (%)
Median; IQR
3.59; 1.90
5.00; 1.74
5.09; 2.58
0.001
(min, max)
(0.6, 12.5)
(2.3, 15.3)
(2.5, 12.8)
Disulphide/total thiol (%)
Median; IQR
3.35; 1.64
4.55; 1.43
4.62; 2.09
0.001
(min, max)
(0.6, 10.0)
(2.2, 11.7)
(2.4, 10.2)
Native thiol/total thiol (%)
Median; IQR
93.29; 3.28
90.90; 2.86
90.76; 4.17
0.001
(min, max)
(80.0, 98.7)
(76.6, 95.6)
(79.6, 95.2)
PASI: Psoriasis Area Severity Index. There was statistical significance between healthy controls and psoriasis patients with PASI ≤ 10 (). There was statistical significance between healthy controls and psoriasis patients with PASI > 10 (). There was statistical significance between psoriasis patients with PASI ≤ 10 and PASI > 10 ().
